

# The Future of CDISC

PharmaSUG Workshop  
La Jolla, CA  
13 September 2013

Rebecca Kush, PhD  
President, CDISC



*Strength through Collaboration*

# Themes for the Future of CDISC

- Develop global research standards faster and better
  - **CDISC Teams and CFAST**
- Make the standards readily accessible
  - **SHARE**
- Support the global trends in healthcare
  - **Healthcare Link**

# What is CDISC?

# Clinical Data Interchange Standards Consortium (CDISC)

- Global, open, multi-disciplinary, vendor-neutral, non-profit standards developing organization (SDO), a 501c3
- Founded 1997, incorporated 2000
- Member-supported (> 300 member organizations: academia, biopharma, service and technology providers and others)
- Liaison A Status with ISO TC 215
- Charter agreement with HL7 (2001->)
- Leadership of Joint Initiative Council (JIC) for Global Harmonization of Standards
- Member of ANSI-led ISO TAG
- Active Coordinating Committees (3C)
  - Europe, Japan, China
- >> 90 countries (18,000 individuals) in participant/contact database

CDISC® Strength Through Collaboration

HOME BLOG SITE MAP FAQ CONTACT SEARCH PORTAL

ABOUT CDISC | STANDARDS & INNOVATIONS | RESOURCES | NEWS | EDUCATION & EVENTS | MEMBERSHIP | MEMBERS ONLY

**CDISC is the Common Language for Clinical Research**

**Volunteer for CDISC!**  
Follow the link.

**CDISC 2011 Annual Report**  
Download your copy of the 2011 CDISC Annual Report Today! Click the image below to download:

**Join CDISC!**  
Read about the benefits of membership and how to join here more...

**What's New**


CDISC Board of Directors Call for Nominations - Deadline 31 July 2012

CDISC International Interchange 2012 - June Newsletter


CDISC President and CEO talks at the CDISC European Interchange in Stockholm!  
Follow the link to view the video on The State of the CDISC Union presented by Dr. Rebecca Kush.

*CDISC Standards are freely available via the website [www.cdisc.org](http://www.cdisc.org)*

# CDISC Operations



# CDISC



# Global Clinical Research Standards End-to-End

Study Start-up  
70-90% Savings

Study Conduct  
40-60% Savings

Analysis and Reporting  
50-60% Savings

## Therapeutic Area Standards

Harmonized through BRIDG Model  
and Controlled Terminology



Protocol  
Representation  
Model  
(PRM)

Study  
Design Model,  
Clinical Trial  
Registration

eCase  
Report  
Forms  
(CDASH)

Laboratory  
(LAB)

Study  
Data Tabulation  
Model (SDTM)

SEND for  
pre-clinical data

Analysis  
Dataset  
Model  
(ADaM)

Operational Data Model (ODM)  
XML Data Exchange

Define.xml

# TA Standards Development - Hx



TB and CV (ACS) elements through  
NIH Roadmap Grants w/ Duke

Polycystic Kidney  
Disease w/ Tufts

Pain w/ Rochester  
through FDA Grant

Virology through  
NIH/FDA Grant



Alzheimer's Disease w/  
C-Path / CAMD

Parkinson's Disease w/  
C-Path / NIH-NINDS


*TB with C-Path/CPTR, TB Alliance, Gates Foundation, IMI...  
MS with C-Path*

2008

Present



# A New Process



# Target Timelines Under New Process

Stage 0	Stage 1	Stage 2	Stage 3		
Scoping, Inputs, Planning	Concept Definition and Modeling	Standards Development (Metadata, Terminology, User Guide, Examples)	Internal Review	Public Review	Publication
Months <1-2	Months 2-4	Months 3-6	Months 6-10+		



## Coalition for Accelerating Standards & Therapies

- In response to CDISC member value surveys and PDUFA V (with the FDA's statement of need for therapeutic area data standards), C-Path and CDISC established CFAST
- CFAST is an **initiative** to accelerate clinical research and medical product development by creating and maintaining data standards, tools and methods for conducting research in therapeutic areas that are important to public health
- Now contributing to CFAST: FDA, TransCelerate Biopharma, NCI EVS, ACRO and IMI

# Therapeutic Area Standards Governance

- Provides Scientific Advice to TAPSC
- Identifies Risks and Opportunities
- Identifies/Engages Relevant Partners

- Prioritizes/Approves Proposals
- Approves Projects & Charters
- Resources & Oversees Projects

**CDISC TA Standards Project Teams**  
**Project Leader +**  
 Clinical leads (SMEs), BRIDG Modeler, Concept Creators, Terminologists, Metadata Analysts, Stats Consultants, Writers, Communications

**Ongoing Maintenance & Enhancement of Foundational CDISC Standards**

## Therapeutic Area Standards Under Development

	Coordinating Organization(s)	Stage 0	Stage 1	Stage 2	Stage 3a	Stage 3b	Stage 3c
	Project Manager	Scoping & Input	Concept Modeling	Standards Development	Internal Review	Public Review	Publication
Alzheimer's V1.1	CPATH/CDISC Jon Neville	Jan	Mar	Jun	<i>Jul</i>	<i>Sep</i>	Q313
Asthma V1	CDISC Rhonda Facile	Jan	Mar	Jun	Jul	<i>Sep</i>	Q413
Cardiovascular Endpoints V1	CDISC/DCRI Amy Palmer	Jun	<i>Jul</i>	<i>Aug</i>			Q114
Multiple Sclerosis V1	CPATH/CDISC Bess Leroy	May	<i>Aug</i>	<i>Jul</i>			Q114
Diabetes V1	TCB/CDISC Rachael Zirkle	Mar	<i>Jun</i>	<i>Aug</i>	<i>Sep</i>		Q114
QT Studies V1	TCB/CDISC John Owen	<i>Jul</i>	<i>Sep</i>				Q214
Traumatic Brain Injury V1	CDISC TBD	<i>Sep</i>					Q214
Hepatitis C V1	TBD	<i>Sep</i>					Q314
Schizophrenia V1	CDISC/DCRI Amy Palmer	<i>Oct</i>					Q314
Oncology	TBD	<i>Oct</i>					

Project Status:  Stage ongoing  Stage completed *Italics = Projected*

## Published Therapeutic Area Standards

<a href="#">Alzheimer's Disease V 1 - Final</a>	<a href="#">Polycystic Kidney Disease V1- Provisional</a>
<a href="#">Pain V1 - Provisional</a>	<a href="#">Tuberculosis V1 - Provisional</a>
<a href="#">Parkinson's Disease V1 - Provisional</a>	<a href="#">Virology V1 - Provisional</a>

# IMI-CDISC-FDA Synergies

## IMI Therapeutic Area projects

- \*Alzheimer's Disease - EMIF
- \*Asthma (Severe) – U-BIOPRED
- Autism
- \*Cancer (Breast, Colon, Lung and Prostate Cancer)
- \*Chronic Pain – EUROPAIN
- \*Diabetes Type II – DIRECT
- \*Neurodegenerative Diseases – Pharma-Cog
- \*Rheumatoid Arthritis – 2 IMI projects
- \*Tuberculosis – PredictTB
- Other US-EU project synergies e.g. TBI, PTSD

\* = FDA Therapeutic Area Priority as well


# CDISC SHARE

A global, accessible electronic metadata library, which through advanced technology, enables precise and standardized data element definitions **and richer metadata** that can be used in applications and studies to improve biomedical research and its link with healthcare.

<http://www.cdisc.org/cdisc-share>

- *Accelerates standards development*
- *Improves standards accessibility*







- Single, trusted, authoritative source for CDISC data standards
- Concepts, metadata, collections, relationships, value sets across the full spectrum of CDISC content
- Links research to healthcare concepts to support interoperability
- Aligned with NCI Semantic Systems

BRIDG, ISO21090

Protocol, CDASH

SDTM, ADaM

Terminologies




**Facilitates Data Exchange**

- Access to data standards
- Source to target mapping & traceability
- Transformation logic


Adapted from Source by Sue Dubman, Sanofi (Genzyme)

# Future Standards will be Built in SHARE: SHARE Business Template Example



- In SHARE:
  - Each variable is a unique object, assembled into metadata sets, domains and standards
  - Each terminology value is an object, assembled into value sets and codelists
  - SHARE templates will reuse component objects, assembling new metadata for new versions of standards and new therapeutic areas
  - Object-level repository will also improve ease of translation

# BRIDG Model Content (Layer 2)



## *Healthcare*

- Quality healthcare
- Informed decisions
- Personalized medicine
- Patient safety and privacy
- Public health
- Improved therapies
- Efficiencies/reduced costs

*Information from healthcare  
(private, aggregated)  
to enable research*




## *Research*

- Discovery of new therapies
- Understanding diseases
- Testing/comparing therapies (CER)
- Assessing efficacy
- Monitoring safety
- Understanding responses (genomics, biomarkers)
- Public health/quality evaluations
- Post-marketing surveillance

*Research findings  
to inform  
healthcare  
decisions*



# Goal: Optimize the Process



~1997


# eSource Data Interchange (eSDI) Initiative

- **Purpose:** FDA initiative to facilitate the use of electronic technology in the context of existing regulations for the collection of eSource data in clinical research

***Note: eSource pertains to collecting data electronically initially through eDiaries, ePatient Reported Outcomes, eData Collection, EHRs***

- **Overarching Goals:**
  - To make it easier for physicians to conduct clinical research,
  - Collect data only once in an industry standard format for multiple downstream uses, and thereby
  - Improve data quality and patient safety
- **Product from multidisciplinary team:**
  - **eSDI Document**
  - **12 requirements for eSource**
  - **Available at [www.cdisc.org/eSDI-document](http://www.cdisc.org/eSDI-document)**
  - **Formed the basis for the Retrieve Form for Data Capture (RFD) Integration Profile**

# Patient Value: Quality of Healthcare, Safety



**HITSP  
Interoperability  
Specification # 158**

*Produces a standard  
core research dataset;  
Enables 21CFR11-compliant  
interoperability and eSource*

# HHS/ONC (U.S. Dept. Health and Human Services Office of the National Coordinator of Health Information Technology)

## Structured Data Capture Initiative, Launched 23 Jan 2012

### The Value of SDC within EHRs



Stage 3 MU  
Learning Health  
System

Advances Stage 3 MU vision to design trusted infrastructure to enable patient information to flow securely from EHRs to other systems, such as research consortia, registries, and bio repositories

- Standards will facilitate the collection of data so that any researcher, clinical trial sponsor, reporting and/or oversight entity can access and interpret the data in electronic format
- Will leverage existing standards such as XML and CDISC Retrieve Form for Data Capture (RFD)

site-specific EHR  
enhancements

system capabilities in order to enable participation in important reporting and research activities


# CDISC- IHE Profiles for EHR-enabled Research

- *make the connection*
  - Retrieve Form for Data-capture (RFD)
- *auto-populate the eCRF*
  - Clinical Research Data (CRD)
  - Drug Safety Content (DSC)
  - Redaction Services
  - Data Element Exchange (DEX)
- *automate collaborative business processes*
  - Retrieve Process for Execution (RPE)
  - Clinical Research Process Content (CRPC)
  - Research Matching (RM)

# Capabilities with Available (Core) Data Standards and Integration Profiles/Interoperability Specifications (Standards-inspired Innovation)

- Dramatic reduction in time and effort to report core data for safety, research, public health
- Can accommodate eDiaries, patient-entered data
- Improved data quality
- Data can be more readily aggregated and analyzed or queried
- Extensible; paves the way for more complex research and clinical genomics for personalized healthcare
- RFD is easily implemented by vendors; endorsed by EHRA

# A National-Scale Learning Health System



**CDISC Leading ESTEL = Essential Standards to Enable Learning**

# Regulatory Agencies and CDISC

- PMDA (Japan) – According to new J3C Chair, plan to adopt CDISC by 2016
  - PMDA leader met with CDISC, J3C and TRI leaders at Japan Interchange 2012
  - PMDA recently announced a CDISC pilot
- CFDA (China) – Visiting U.S. in November; requested one-day training in CDISC in PA and half-day meeting with CDISC
  - In discussions with CDISC/C3C for several years

# EMA

**From:** Peter Van Reusel (Chair) to E3C

**Subject:** FW: EMA policy on publication and access to clinical-trial data released for public consultation

Dears,

FYI below, the EMA has released the draft policy for public review. The policy will come into effect on Jan 2014. Data standards are mentioned as follows:

242 Wherever technically possible, analysable, de-identified raw CT data shall be made available for  
243 downloading in the format in which they have been analysed by the applicant, submitted and  
244 evaluated. For the time being, this can be according to CDISC (Clinical Data Interchange Standards  
245 Consortium) or other appropriate standard. In future, CDISC shall be the required standard, in line  
246 with future guidance from the Agency. No conversion of formats is recommended, either by the  
247 marketing-authorisation holder or the Agency.

## • **Guidances & Notices in Process**

eCTD Guidance	<ul style="list-style-type: none"> <li>• Published January 3, 2013</li> </ul>
eSource Guidance	<ul style="list-style-type: none"> <li>• Publication November 20, 2012</li> <li>• Comment Review Completed</li> <li>• Final Guidance in Clearance</li> </ul>
eStudy Data Guidance	<ul style="list-style-type: none"> <li>• Revised Draft Completed</li> <li>• New Draft in Clearance</li> </ul>
Therapeutic Area Project Plan	<ul style="list-style-type: none"> <li>• Plan in Clearance</li> </ul>

## • **Federal Register Notices**

- SDTM 3.1.1 retirement date
- Data Standards Strategy and Action Plan

# How can you and your companies benefit from CDISC?

Participate in the Interchange - 6-7 November, Bethesda, MD  
Keynoters: Drs. Mark McClellan, Dr. Lisa LaVange (FDA Statistics)



- ✓ Join a team; attend the INTRACHanges
- ✓ Comment on the standards during public reviews
- ✓ Use the standards from the start – CDASH (and Protocol)
- ✓ Participate in the Tuft's CSDD Study
- ✓ Take authorized CDISC training courses
- ✓ Make sure your organization is a member of CDISC and you are on the mailing list; participate in the CDISC Advisory Council

# Communication is Essential

## CDISC eNewsletter

- Hot Topics
- Success Stories
- Technical News
- FAQs
- Blogs and Press Releases
- 3C and User Networks
- Membership
- Education
- Networking Events

## CDISC Annual Report



*Sign up online to our e-mail list!*



facebook

“All too many observations lie isolated and forgotten on personal hard drives and CDs, trapped by technical, legal and cultural barriers.”

*Nature, September 2009*

**Quality Improvement**

**Enablers**

**CDISC is more than  
Standards!**

**Speed**

**Process Redesign**

**Workflow Integration**

***Standards-inspired Innovation***

**Resource Savings**

**Strength through collaboration**